9 Links Between Menopause and Hidradenitis Suppurativa That Explain Changing Skin Flares
What so many women describe is the particular cruelty of thinking their HS was finally becoming manageable — and then perimenopause arriving and blowing the whole thing open again. Or worse, developing painful nodules for the first time at 47 and being told it's just an ingrown hair. HS deserves to be taken seriously at every age, and the hormonal connection at midlife is real, documented, and far too rarely discussed in the dermatologist's office.
Learn more about Rose →Estrogen Decline Removes a Natural Anti-Inflammatory Shield
Estrogen has well-documented anti-inflammatory properties, helping to regulate the immune response in skin tissue and suppress the cytokine activity that drives HS lesions. As estrogen levels fall during perimenopause, that protective dampening effect weakens, leaving follicular inflammation — the root mechanism of HS — less restrained. Women who had relatively stable HS during their reproductive years often notice the shift toward more frequent or more severe flares tracking closely with the onset of hormonal decline.
Relative Androgen Dominance Drives Follicular Occlusion
When estrogen drops faster than androgens during perimenopause, the ratio shifts toward relative androgen dominance — and androgens are a primary driver of the follicular plugging that initiates HS lesions. Androgens stimulate sebaceous gland activity and alter keratinocyte behavior, increasing the likelihood of the follicular occlusion that starts the HS disease process. This is the same mechanism that explains why HS disproportionately affects women of reproductive age and why it often first appears or worsens around hormonal inflection points like puberty, pregnancy, and menopause.
The Menstrual Cycle's Disappearance Removes a Flare Predictor
Many women with HS learn to anticipate flares in the premenstrual window, when progesterone peaks and then falls sharply — and that predictability, while painful, at least allowed for preparation and management. As cycles become irregular in perimenopause, that hormonal rhythm becomes chaotic, and the flare pattern that women had mapped over years suddenly stops making sense. The loss of cycle-linked predictability is not just frustrating; it can delay recognition that HS is changing and make it harder to identify triggers or assess whether a treatment is working.
Insulin Resistance, Which Peaks at Menopause, Is an Independent HS Trigger
HS has a strongly established association with insulin resistance and metabolic syndrome, both of which become significantly more common after menopause due to the metabolic effects of estrogen loss. Insulin resistance elevates circulating insulin and IGF-1, which in turn stimulate androgen production and sebaceous gland activity, compounding the hormonal drivers already disrupted by menopause. Women who develop HS for the first time in their late 40s or 50s may be experiencing the convergence of two independent processes — menopausal hormonal change and worsening metabolic health — that together cross a threshold the body previously managed.
Perimenopausal Weight Shifts Increase Friction and Occlusion in HS-Prone Areas
Estrogen loss redistributes body fat toward the abdomen and increases the prevalence of skin folds in areas like the groin, inner thighs, and inframammary region — precisely the zones where HS most commonly occurs. Increased friction and occlusion in these areas are well-recognized mechanical triggers for HS flares, independent of hormonal changes. The combination of hormonally driven inflammation and physically worsened microenvironments in HS-prone skin creates a compounding effect that can accelerate disease progression during the menopausal transition.
Perimenopausal Sleep Disruption Elevates Cortisol and Worsens Flares
Poor sleep — one of the most common and disruptive symptoms of perimenopause — drives chronic elevations in cortisol, the body's primary stress hormone. Elevated cortisol has been linked to worsening inflammatory skin conditions including HS, likely through its effects on immune dysregulation and the skin barrier. Women managing both sleep deprivation and HS often find themselves in a feedback loop where pain from flares disrupts sleep further, and that disrupted sleep makes the next flare worse.
The Gut-Skin Axis Becomes More Disrupted at Menopause
Emerging research links changes in the gut microbiome to HS severity, with dysbiosis — microbial imbalance in the gut — appearing to amplify systemic inflammation relevant to HS. Estrogen plays a regulatory role in the gut microbiome through a mechanism involving the estrobolome, and its decline at menopause is associated with measurable shifts in gut bacterial diversity. While this connection is still being mapped, the convergence of menopausal gut changes and HS-related inflammation is a plausible and increasingly studied pathway that may help explain midlife flare escalation.
HRT Can Improve or Complicate HS Depending on Formulation
Hormone replacement therapy is not a simple win or loss for women with HS — the type of hormones used matters significantly. Estrogen-only or estradiol-based therapy generally shows a beneficial effect on HS in case series and observational data, consistent with estrogen's anti-inflammatory and androgen-opposing role. However, certain progestogens with androgenic activity — notably older synthetic progestins like norethisterone — may worsen HS, which means that women with HS discussing HRT with their doctor should specifically raise the question of progestogen type and ideally use body-identical progesterone or a non-androgenic progestogen.
New-Onset HS After 45 Is Frequently Misdiagnosed and Undertreated
Women who develop HS for the first time during perimenopause are often older than the typical presentation age that clinicians associate with the condition, leading to misdiagnosis as recurrent boils, folliculitis, or infected cysts. Diagnostic delay for HS already averages seven to ten years across all age groups, and the menopausal context may add additional confusion for both patients and clinicians who don't think of HS as a midlife disease. Recognizing that hormonal disruption can genuinely trigger new-onset HS in women in their 40s and 50s is essential to getting an accurate diagnosis and appropriate care before scarring and tunneling progress.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.